Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer

Yu, Jun; Liyan, Jin; Jiang, Linhua; Gao, Ling; Zhou, Jin; Hu, You; Li, Wei; Zhi, Qiaoming; Zhu, Xinguo

doi:10.2174/1871520615666150716110406

Cited by 44 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included for the final systematic review (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Ahmed et al , 2012; Kanaan et al , 2012; Wang and Zhang, 2012; Wang et al , 2012b; Brunet Vega et al , 2013; Giraldez et al , 2013; Hofsli et al , 2013; Kanaan et al , 2013; Liu et al , 2013; Luo et al , 2013; Toiyama et al , 2013; Yu et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Perilli et al , 2014; Xu et al , 2014; Zanutto et al , 2014; Zheng et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Ghanbari et al , 2015; Ho et al , 2015; Ramzy et al , 2015; Wang et al , 2015; Li et al , 2015; Li et al , 2016; Sun et al , 2016; Wang et al , 2016; Yu et al , 2016) and of these 19 were included in the meta-analysis (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Kanaan et al , 2012; Wang and Zhang, 2012; Wang et al , 2012b; Liu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Xu et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Li et al , 2016; Sun et al , 2016; Wang et al , 2016; Yu et al , 2016). Of these 34 studies, 20 (59%) used plasma (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Ahmed et al , 2012; Kanaan et al , 2012; Wang et al , 2012b; Giraldez et al , 2013; Kanaan et al , 2013; Luo et al , 2013; Zhang et al , 2013; Du et al , 2014; Perilli et al , 2014; Xu et al , 2014; …”

Section: Resultsmentioning

confidence: 99%

“…Sixteen of the 34 studies performed miRNA screening studies (Ng et al , 2009; Ahmed et al , 2012; Kanaan et al , 2012; Wang et al , 2012b; Brunet Vega et al , 2013; Giraldez et al , 2013; Hofsli et al , 2013; Kanaan et al , 2013; Luo et al , 2013; Zheng et al , 2014; Xu et al , 2014; Ghanbari et al , 2015; Ho et al , 2015; Wang et al , 2015; Li et al , 2015; Sun et al , 2016) in order to identify dysregulated miRNAs in the plasma or serum of CRC cases compared with healthy controls, whereas the remaining 18 studies identified miRNAs for assessment based on the literature or based on their own prior studies (Huang et al , 2010; Pu et al , 2010; Wang and Zhang, 2012; Liu et al , 2013; Yu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Perilli et al , 2014; Zanutto et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Ramzy et al , 2015; Li et al , 2016; Wang et al , 2016; Yu et al , 2016). A total of 617 miRNAs were differentially expressed between CRC and healthy controls in these screening studies, and of these, 69 miRNAs were found to be significantly dysregulated in validation or subsequent studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

Background:Colorectal cancer (CRC) is common and associated with significant mortality. Current screening methods for CRC lack patient compliance. microRNAs (miRNAs), identified in body fluids, are negative regulators of gene expression and are dysregulated in many cancers, including CRC. This paper summarises studies identifying blood-based miRNAs dysregulated in CRC compared with healthy controls in an attempt to evaluate their use as a screening tool for the diagnosis of CRC.Methods:A search of electronic databases (PubMed and EMBASE) and grey literature was performed between January 2002 and April 2016. Studies reporting plasma or serum miRNAs in the diagnosis of CRC compared with healthy controls were selected. Patient demographics, type of patient sample (serum or plasma), method of miRNA detection, type of normalisation, and the number of significantly dysregulated miRNAs identified were recorded. Statistical evaluation of dysregulated miRNAs using sensitivity, specificity, and area under the curve (AUC) was performed.Results:Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included. A total of 31 miRNAs were found to be either upregulated (n=17) or downregulated (n=14) in CRC cases as compared with controls. Fourteen studies identified panels of ⩾2 dysregulated miRNAs. The highest AUC, 0.943, was identified using a panel of 4 miRNAs with 83.3% sensitivity and 93.1% specificity. Meta-analysis of studies identifying a single dysregulated miRNA in CRC cases compared with controls was performed. Overall sensitivity and specificity of 28 individual miRNAs in the diagnosis of CRC were 76% (95% CI 72%–80%) and 76% (95% CI 72%–80%), respectively, indicating good discriminative ability of miRNAs as biomarkers for CRC. These data did not change with sensitivity analyses.Conclusions:Blood-based miRNAs distinguish patients with CRC from healthy controls with high sensitivity and specificity comparable to other common and invasive currently used screening methods for CRC. In future, miRNAs may be used as a relatively non-invasive blood-based marker for detection of CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…25 Recently, similar circulating biomarker, serum miR-372, was also found to be a novel and non-invasive tumor biomarker for ECRC diagnosis. 26 Moreover, using peripheral plasma to determine miRNAs expressing levels was relatively cheap, time saving, and easy to perform.…”

Section: Discussionmentioning

confidence: 99%

Circulating miR-1826 in plasma correlates with circulating tumor cells and is a prognostic marker in colorectal cancer

Han

et al. 2017

Tumour Biol.

Self Cite

View full text Add to dashboard Cite

Our previous study showed that miR-1826 was a newly identified oncogenic non-coding RNA in colorectal cancer. But the potential relationship between miR-1826 and tumor metastasis has not been fully elucidated. The purpose of this study was to evaluate the clinical significance of circulating miR-1826 and its possible associations with circulating tumor cells in colorectal cancer. Our results first found that serum miR-1826 was significantly upregulated in colorectal cancer patients, compared with that in healthy volunteers (p = 0.003). Similar results were also found in colorectal cancer with distant metastasis (p = 0.001) and advanced colorectal cancer (p < 0.001) patients, respectively. Clinicopathological analysis implied that circulating miR-1826 was positively associated with pT stage (p = 0.026), lymphatic metastasis (p = 0.034), distant metastasis (p = 0.012), and tumor-node-metastasis stage (p = 0.020). Besides, our univariate and multivariate analyses demonstrated that high serum miR-1826 expression could act as a prognostic and independent factor for overall survival of colorectal cancer patients (p < 0.05), which led to a poorer 5-year overall survival rate (p = 0.025). The area under the curve value of circulating miR-1826 was up to 0.848 ± 0.043, which strongly suggested serum miR-1826 as an effective diagnostic biomarker in colorectal cancer patients (p < 0.001). Our subsequent experiments demonstrated that patients with high level of circulating tumor cells showed a higher level of miR-1826 expression, compared with the circulating tumor cell-negative patients (p = 0.011). Similar results also showed that the amount of circulating tumor cells in high miR-1826 group was significantly higher than that in low miR-1826 group (p = 0.001). Furthermore, the relationship between serum miR-1826 and circulating tumor cells was analyzed using SPSS software and a significant logarithmic relationship was found, which meant that circulating miR-1826 closely correlated with the amount of circulating tumor cells in colorectal cancer patient serum (r = 0.283, p < 0.01). Our findings strongly suggested that serum miR-1826 could serve as an effective and non-invasive biomarker for diagnosis and prognosis of colorectal cancer. Circulating miR-1826 may be an important target in colorectal cancer therapy.

show abstract

“…Expression of 12 miRNAs in plasma samples was measured using RT-PCR, and the result showed that miR-92a was upregulated in patients with advanced colorectal neoplasia than healthy controls [17]. In a two-phase case-control test designed to identify serum miRNAs as Citation early CRC diagnosis was significantly higher than that of combined tumor markers (CEA, CA125 and CA199) (0.854 vs. 0.613) [24]. It was worth mentioning that serum miR-1290 could discriminate CRC patients from healthy control, yielded an AUC value of 1.00, sensitivity of 100%, specificity of 100% [25].…”

Section: Values Of Circulating Mirnas As Diagnostic Biomarkersmentioning

confidence: 99%

Circulating MicroRNAs in Colorectal Cancer

Huang¹,

Ge²,

Hu³

et al. 2017

J Mol Genet Med

View full text Add to dashboard Cite

IntroductionWith increasing incidence, colorectal cancer (CRC) remains the second most common cancer in women and the third in men, despite the improved screening techniques, most patients diagnosed CRC are at late stage, CRC is the second leading cause of cancer-related death worldwide [1]. Complete tumor resection by surgery is the main therapeutic modality, it was reported that 5-year survival rates were in range from 93.2% for the earliest stage to 6.6% for advanced disease at diagnosis according to Duke's stage. So, good prognosis of CRC is linked to stage at earlier diagnosis. However, due to asymptomatic in early stage of CRC, many cases were detected at late stage. In clinical practice, colonoscopy is used in the diagnosis and treatment of CRC, but has not yet been wide-used as a screening tool because of some limitations, such as the requirements of bowel preparation, cost burden and perforation risk [2]. In addition, fecal occult blood test (FOBT), some convenient circulating blood biomarkers, including the most frequently used marker carcinoembryonic antigen (CEA), carbohydrate antigens, CA125, CA153 and CA199, are lack of sufficient sensitivity or specificity. For example, the specificity of FOBT is about 95%, while the sensitivity of is around 70% to 75% [3], the sensitivity and specificity of CEA is 60% and 34%, respectively [4]. Therefore, new strategies and novel biomarkers with the characters of detection, staging and prediction of outcome are highly desirable and being explored in order to make optimized treatment prescription and to improve prognosis for CRC patients.A growing number of researches focus on small non-coding RNA molecules, microRNAs (miRNAs, miRs), which play multiple roles in variety of biological processes, including cancer [5][6][7]. Since 2008, tumor-derived miRNAs were described present stablely in circulating blood, as circulating-based markers for cancer detection [8]. Consider the detection of circulating miRNAs have the advantages of simple, inexpensive and noninvasive, combined with the remarkable stability characteristics of mature miRNAs due to the miRNA-Argonaute-protein complex, the discovery of circulating miRNAs as novel biomarkers for cancer intervention has been widely explored [9,10]. Growing evidences have indicated that aberrant expression of circulating miRNAs has an association with cancer including CRC. The diagnostic and prognostic value of circulating miRNAs exhibited in screening and monitoring, predicting recurrence or metastasis including lymph node, vessel, peritoneal invasion or distant metastasis, stratification by TNM stage or even histological differentiation grade, and few are associated with drug resistance, chemoradiosensitivity, tumor size and gender. This review covers recent researches in circulating miRNAs and their variety potential values correlated with CRC (Figure 1). Experiment FlowExperiment flow for the identification of CRC-related circulating miRNAs apply step-wise strategy. First experiment samples are selected according to dif...

show abstract

Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer

Cited by 44 publications

References 0 publications

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

Circulating miR-1826 in plasma correlates with circulating tumor cells and is a prognostic marker in colorectal cancer

Circulating MicroRNAs in Colorectal Cancer

Contact Info

Product

Resources

About